



Single-use technology and sustainability: quantifying the environmental impact

Bill Flanagan

Director, Ecoassessment Center of Excellence, GE

1 November 2016

Imagination at work

Agenda

Biopharmaceutical industry—business drivers

Single-use technologies can enable today's outcomes

Relationship of single-use technology and sustainability

GE's new life cycle assessment study

Insights to guide your single-use journey

Questions



Drug development and manufacturing is a highly complex and competitive industry

Desired outcomes

Higher productivity, titer/yield

Higher plant utilization

Multi-product, flexible manufacturing

Less variability, failures, and waste

Higher efficiency

Higher manufacturing quality standards

Fewer
blockbusters


Ever increasing
competition
(biosimilars)

Relentless cost
pressure

Localized
manufacturing



Single-use technologies enabling today's outcomes



Benefits of single-use technology

Sustainability

Flexibility

Cleaning

Process economy



Relationship of single-use and sustainability




Image courtesy of division of Industrial Biotechnology, KTH/Biotechnology



GE Healthcare FlexFactory™ biomanufacturing operations in Marlborough, MA, USA

- Industry shift towards single-use technology
- Understand environmental trade-offs associated with technology shift
- How can single-use technology help achieve sustainability goals?



Assess overall environmental impact throughout a product or service's life cycle



More than just carbon footprint

Understanding the net environmental impact of a product/service across its value chain, how and where to make improvements

- Support decisions
- Evaluate alternatives
- Prioritize opportunities for improvement
- Mitigate environmental issues



2010 to 2012 LCA results

WAVE Bioreactor™ system +
ReadyToProcess™ full process train for mAb
production


Purpose/driver of LCA

- To compare the potential environmental impacts of multi-use vs single-use process technology

Results/lessons learned

- Single-use technology exhibits lower environmental impact across the full life cycle
 - reduction of water for injection (WFI), process water, steam
 - less requirement for cleaning and sanitization in place (CIP, SIP)
- End-of-life impacts negligible compared to use phase and supply chain

Full process train, 2000 L scale




**Result was unexpected,
counterintuitive, and only accessible
through detailed LCA**

Pietrzykowski M. *et al*, An Environmental Life Cycle Assessment Comparison of Single-Use and Conventional Process Technology for the Production of Monoclonal Antibodies, *J. Clean. Prod.* **41**, 150-162 (2013).



Bioprocess evolution requires new insights

- Expansion of single-use capability into new geographies
- Trend towards increased use of facilities with optimized floor plans
- Incorporate broader range of single-use technologies
- Support customer interest and requests for new LCA results



LCA study being updated and expanded

2010–2012 LCA study

mAb process

Stainless steel and single-use retrofit

WAVE Bioreactor™ system and ReadyToProcess™ portfolio

2016 LCA study

mAb and vaccine processes

Stainless steel, single-use retrofit, and hybrid

Xcellerex™ bioreactors, WAVE Bioreactor system, HyClone™ portfolio, ÄKTA™ ready system, ReadyToProcess portfolio

Geography considerations


End-of-life disposal options



LCA study scope, phase I



Image courtesy of division of Industrial Biotechnology, KTH/Biotechnology



Like the GE Healthcare FlexFactory™ biomanufacturing operations in Marlborough, MA, USA



mAb

200 L
500 L
2000 L
2 × 2000 L
4 × 2000 L

200 L
500 L
2000 L
2 × 2000 L
4 × 2000 L

200 L
500 L
2000 L
2 × 2000 L
4 × 2000 L

6 g/L titer | 10-batch campaign

Participants: Ecoassessment Center of Excellence at GE, GE Healthcare, Quantis, BioPharm Services, Ltd.



LCA study scope, phase II





Image courtesy of division of Industrial Biotechnology, KTH/Biotechnology



Like the GE Healthcare FlexFactory™ biomanufacturing operations in Marlborough, MA, USA



mAb

200 L
500 L
2000 L
2 × 2000 L
4 × 2000 L

200 L
500 L
2000 L
2 × 2000 L
4 × 2000 L

200 L
500 L
2000 L
2 × 2000 L
4 × 2000 L



Vaccine

50 L
200 L
500 L

LCA model can explore environmental improvement opportunities in stainless steel, single-use, or hybrid

50 L
200 L
500 L



LCA study scope, phase II





Image courtesy of division of Industrial Biotechnology, KTH/Biotechnology



Like the GE Healthcare FlexFactory™
biomanufacturing operations in Marlborough,
MA, USA



mAb

200 L
500 L
2000 L

200 L
500 L
2000 L

200 L
500 L
2000 L

Third party critical review to be performed



Vaccine

50 L
200 L
500 L

LCA model can explore
environmental improvement
opportunities in stainless steel,
single-use, or hybrid

50 L
200 L
500 L



Hybrid process configuration

Process	% Single-Use
Traditional	0%
Hybrid	62%
SU retrofit	100%


Unit Op Number	Unit Op Name	Equipment used for comparison					
		SU Retrofit		Hybrid SU-Trad			
		Nominal Technology	#SU	Nominal Technology	#SU	#Trad	%SU
1	N-2 Seed	WAVE	7.0	WAVE	6.5	0.0	100%
2	N-1 Seed	Xcellerex XDR	11.0	Xcellerex XDR	6.5	1.0	87%
3	Production	Xcellerex XDR	14.0	ss bioreactor	4.0	7.0	36%
4	Clarification	SU Harvest filter skid and holder, SU Depth filter & SU Polishing filter	11.6	ss filter housing + depth filtration	3.0	4.0	43%
5	Bioburden reduction I	ss filter housing + biob. filter	16.6	ss filter housing + biob. filter	12.0	1.0	92%
6	Protein A	AKTA system + AxiChom 450 column MabSelect SuRe resin	20.0	ss column + protein A resin	6.5	9.0	42%
7	Virus Inactivation	Xcellerex XDUO	16.2	ss mixing vessel	10.4	2.0	84%
8	Bioburden reduction II	Filter Capsules - Bioburden Filter	11.6	Filter Capsules - Bioburden Filter	9.0	1.0	90%
9	Sterile filtration II	Filter capsule/sterile filtration	11.6	ss filter housing + sterile filter	9.0	1.0	90%
10	IEX Bind & Elute	AKTA system + pre-packed column Capto S ImpAct resin	18.0	ss column + IEX resin	6.5	12.0	35%
11	AIEX Flow Through	Millipore Pro Magnus Viral filter skid and holder + Viresolve Pro	18.0	ss column + AIEX resin	4.4	6.0	42%
12	Viral Filtration	Millipore Pro Magnus Viral filter skid and holder + Viresolve Pro	15.9	ss filter housing + viral filter	3.0	4.4	41%
13	UF/DF	TFF SS system (UniFlux) + UF filter (Pellicon Cassettes)	15.0	TFF ss system + UF filter	3.0	1.4	68%
14	Sterile filtration II	Peristaltic pump +Filter capsule/sterile filtration	1.3	ss filter housing + sterile filter	1.2	3.2	27%
Total					85.0	53.0	62%



What is included
in the life cycle?





mAb bioprocessing configurations studied



biob. = bioburden, CIP/SIP = cleaning/sanitization in place, IEX = ion exchange chromatography, prep. = preparation, UF/DF = ultrafiltration/diafiltration
 Note: General unit operations shown; configuration can change due to scale, product choice, technologies used, etc.

Environmental impact assessment




Joliet O. et al, IMPACT 2002+: a new life cycle impact assessment methodology, *Int. J. Life Cycle Assess* **8**(6), 324-330 (2003) as adapted by Quantis in version Q2.22 of [IMPACT 2002+: User Guide](#)

LCI = life cycle inventory




Bioprocess modeling and data collection



Case studies



Single-use LCA results viewer



Looking at the LCA results from three different bioprocess perspectives



US-based, medium-sized
biotechnology company
expanding capacity



Large multi-national
biopharmaceutical company
expanding global capacity



Large multi-national
biopharmaceutical company
upgrading existing stainless
steel process



Does the increased
use of plastics mean
my environmental
impact will increase?




US-based, medium-sized
biotechnology company
expanding capacity



Up to 55% reduction in life cycle impact across the five environmental impact categories

Single-use technologies provide a nearly 55% reduction in total impact for some environmental impact categories, some reduction in all, compared with traditional technologies

North American East Coast,
2 × 2000 L processing scale



SU Retrofit = single-use facility (retrofit modeling), Traditional = traditional stainless steel facility




Preliminary results

Hybrid traditional-SU process configuration captures proportional environmental benefit

A hybrid traditional-SU process chain captures proportional benefit, with greater improvements for conversion of upstream unit processes

North American East Coast,
2 × 2000 L processing scale



Hybrid Traditional-SU = a hybrid process configuration (retrofit), Traditional = traditional stainless steel facility




Preliminary results

Differences in impact during a product's lifecycle

The single-use process scenario has a larger share of impact in the supply chain, while greatly reducing the impact in use

End of Life impacts small relative to other life cycle stages

North American East Coast,
2 × 2000 L processing scale




SU Retrofit = single-use facility (retrofit modeling), Traditional = traditional stainless steel facility



Preliminary results


What are the regional impacts, and how do they affect water and energy footprint?



Large multi-national
biopharmaceutical company
expanding global capacity



The carbon footprint savings vary among the three locations examined




SU Retrofit = single-use facility (retrofit modeling), Hybrid Traditional-SU = a hybrid process configuration (retrofit), Traditional = traditional stainless steel facility



Preliminary results

The water use savings vary among the three locations examined




SU Retrofit = single-use facility (retrofit modeling), Hybrid Traditional-SU = a hybrid process configuration (retrofit), Traditional = traditional stainless steel facility



Preliminary results

The energy use savings vary among the three locations examined



SU Retrofit = single-use facility (retrofit modeling), Hybrid Traditional-SU = a hybrid process configuration (retrofit), Traditional = traditional stainless steel facility



Preliminary results


How will expanding capacity change my carbon footprint?



Large multi-national
biopharmaceutical company
upgrading existing stainless
steel process




Achieving carbon footprint reduction goals



Preliminary results

Achieving carbon footprint reduction goals




SU Retrofit = single-use facility (retrofit modeling)
Hybrid Traditional-SU = a hybrid process configuration (retrofit)
Traditional = traditional stainless steel facility



Preliminary results

Achieving carbon footprint reduction goals




SU Retrofit = single-use facility (retrofit modeling)
Hybrid Traditional-SU = a hybrid process configuration (retrofit)
Traditional = traditional stainless steel facility



Preliminary results

Achieving carbon footprint reduction goals




SU Retrofit = single-use facility (retrofit modeling)
Hybrid Traditional-SU = a hybrid process configuration (retrofit)
Traditional = traditional stainless steel facility



Preliminary results

Achieving carbon footprint reduction goals



SU Retrofit = single-use facility (retrofit modeling)
Hybrid Traditional-SU = a hybrid process configuration (retrofit)
Traditional = traditional stainless steel facility



Preliminary results

Region of choice for facility *does* contribute significantly to environmental impact due to transport and grid differences

Using single-use technologies results in reduced environmental impact of mAb production...usually

Single-use disposal at end-of-life does *not* contribute significantly to environmental impact



Hybrid traditional-SU configuration results in proportional environmental impact reductions

Traditional processes affected most by WFI energy use; SU affected most by distance/mode of transport

Environmental impact of traditional processes can be improved by strategically converting unit processes to SU



What is your scenario?

This is an ongoing, collaborative study addressing customer sustainability questions

What are your key questions relative to single-use and sustainability?

Contact us!



Acknowledgements

BioPharm Services

Adriana Lopes

Andrew Sinclair

Quantis International

Carter Reeb

Jon Dettling

GE Healthcare

Amit Dua

Bill Whitford

Johan Rosenquist

Mia Bennemo

Karolina Busson



GE, the GE Monogram, imagination at work, ÄKTA, FlexFactory, HyClone, KUBio, ReadyCircuit, ReadyMate, ReadyToProcess, WAVE Bioreactor, and Xcellerex are trademarks of General Electric Company.

ReadyMate: This product is covered by US patent number 6,679,529 B2 owned by Johnson & Boley Holdings, LLC and licensed to GE Healthcare companies.

BioSolve is a trademark of Biomatrix, Inc. ecoinvent is a trademark of ecoinvent Association. Excel and Microsoft are registered trademarks of Microsoft Corporation. SimaPro is a trademark of PRé Consultants BV.

© 2016 General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

For local office contact information, visit www.gelifesciences.com/contact

www.gelifesciences.com

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden

October 2016 29237716AA Printed in USA

